China is now the world's second-largest producer of orthopedic robotic surgery research. A 2024 meta-analysis of 17 studies and 1,741 patients examined Chinese robotic systems — here's what it found.
To understand why China's robotic orthopedic surgery data matters, start with volume. According to data published in the Chinese Medical Journal (China Artificial Joint Annual Data Report, 2021):
China's Orthopedic Surgery Volume: The Foundation
To understand why China's robotic orthopedic surgery data matters, start with volume. According to data published in the Chinese Medical Journal (China Artificial Joint Annual Data Report, 2021):
- Total hip arthroplasty (THA): grew from 168,040 procedures (2011) to 577,153 procedures (2019) — a 2.4x increase in under a decade
- Total knee arthroplasty (TKA): grew from 53,880 (2011) to 374,833 (2019) — a nearly 6x increase
- Total joint replacements in China exceeded 900,000 cases in 2019
By 2023, the Chinese artificial joint market reached USD 597 million, with a projected 7.8% compound annual growth rate through 2030. This scale of volume generates surgical expertise that directly benefits clinical outcomes.
The Robotic Surgery Meta-Analysis
A 2024 network meta-analysis published in International Orthopaedics (PMC11658206) analyzed 17 studies involving 1,741 patients to compare robotic-assisted versus conventional total hip arthroplasty, specifically examining Chinese robotic systems including YUANHUA, Tianji, TRex, and RO.
Key Finding: Leg Length Discrepancy
Leg length discrepancy (LLD) after hip replacement is one of the most common sources of patient dissatisfaction and a driver of revision surgery. The meta-analysis found that leg length discrepancy was significantly smaller with Chinese robotic systems (TRex, RO) compared to conventional total hip arthroplasty.
This is a clinically important finding: robotic assistance improves the precision of implant placement, reducing the risk of unequal leg length post-operatively.
China's Research Output: 2nd in the World
A 2025 global bibliometric analysis of orthopedic robotic surgery publications ranked countries by research output:
- USA: 338 articles
- China: 152 articles — 2nd globally
- South Korea, Germany, UK following
China's 28-fold increase in robotic surgery publications over the past decade reflects both the growth in clinical volume and the research infrastructure to analyze outcomes systematically.
Adoption Rates Among Chinese Surgeons
A 2023 survey of 372 Chinese orthopedic surgeons found that 28% (104 surgeons) had already performed robotic-assisted joint arthroplasty. The barriers to wider adoption — cost and training — mirror those seen globally, and adoption is accelerating as robotic systems become more available in Class A hospitals.
Chinese-Developed Robotic Systems
Unlike a decade ago when robotic surgery in China relied exclusively on imported platforms (Mako, ROSA), China has now developed its own orthopedic robotic systems:
- Tianji Robot (TINAVI Medical Technologies) — one of the first domestically approved orthopedic surgical robots in China, used for spine and joint procedures
- YUANHUA — used for hip arthroplasty guidance
- TRex and RO systems — evaluated in the 2024 meta-analysis
Domestic development has driven down costs significantly compared to imported platforms, making robotic-assisted orthopedic surgery accessible in more Chinese hospitals.
What This Means for International Orthopedic Patients
For patients considering hip or knee replacement in China:
- Top-tier hospitals offer robotic-assisted arthroplasty at costs typically 40–60% below US pricing even for robotic procedures
- Surgical volume at major Chinese centers often exceeds 1,000+ joint replacements per year — generating clinical experience that outperforms most Western centers
- Published data now demonstrates that Chinese robotic systems achieve outcomes (leg length accuracy, component alignment) comparable to global platforms
Panda Touring Care works with orthopedic departments at Class A hospitals in Beijing, Shanghai, and Shenzhen with active robotic surgery programs. We can provide hospital-specific volume data and surgeon credentials as part of the pre-admission evaluation process.
Sources: Chinese Medical Journal, China Artificial Joint Annual Data Report, 2021; International Orthopaedics meta-analysis, 2024 (PMC11658206); Journal of Robotic Surgery, 2025; Grand View Research, 2024.